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olyunsaturated Fatty Acids
nd the Post-Infarct Patient
Recipe for Baroreflex Health?*
ohn Floras, MD, DPHIL, FRCPC, FACC,
kshay Bagai, MD
oronto, Canada
obust neural regulation of the heart and circulation is
undamental to cardiovascular health. Conversely, in the
ost-infarct population (1) and in patients with heart failure
with or without coronary artery disease) (2,3), impaired
rterial baroreflex sensitivity (BRS) (i.e., a blunted reflex
eart rate [HR] response to stimulation or unloading of
rterial baroreceptors) and blunted heart rate variability
HRV) are 2 independent, primarily vagally mediated,
arkers of total cardiac mortality and sudden cardiac death
SCD). These events are attenuated by interventions such as
eta-blockade and exercise-training, which augment vagal
rive and diminish sympathetic tone. However, contempo-
ary therapy does not eliminate SCD; some high-risk
atients are intolerant or non-adherent to these prescrip-
ions, and there are limitations to device therapy as a global
ealth strategy. Thus, there remains a need for additional
imple and inexpensive interventions to decrease the occur-
ence of SCD.
See page 1600
Results of randomized trials involving post-infarct pa-
ients have stimulated interest in piscine omega-3 polyun-
aturated fatty acids (n-3 PUFAs), primarily eicosapenta-
noic acid (EPA) and docosahexaenoic acid (DHA), for this
urpose. In the DART (Diet and Reinfarction Trial), men
dvised to supplement their diet with either 2 weekly
ervings of fatty fish or daily fish oil capsules experienced a
9% reduction in all-cause mortality and 32% fewer deaths
rom ischemic heart disease (4). In the GISSI (Gruppo
taliano per lo Studio della Sopravvivenza nell’Infarto mio-
ardico acuto-1) Prevenzione Trial, 11,324 patients were
andomized to a daily supplement of either 1 g n-3 PUFAs,
itamin E, both, or neither. After 3.5 years, there were
elative risk reductions of 45% in SCD and 20% in all-cause
ortality in the n-3 PUFA group, with the former evident
ithin 4 months of randomization (5).
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine, University Health Network and Mount Sinai
ospital, University of Toronto, Toronto, Canada. Dr. Floras holds the Canadar
esearch Chair in Integrative Cardiovascular Biology and is a Career Investigator of
he Heart and Stroke Foundation of Ontario.Omega-3 polyunsaturated fatty acids might reduce vul-
erability to ventricular arrhythmias after myocardial infarc-
ion by acting directly on myocyte sodium and calcium
urrents (6) or indirectly, by restoring vagal HR modulation.
hristensen et al. (7) reported a dose-dependent increase in
RV in healthy men, but not in women, after 12 weeks of
aily supplementation with either 2.0 g or 6.6 g n-3 PUFAs
7). Earlier, these authors had randomized 55 post-
yocardial infarction patients with an ejection fraction
40% to 12 weeks of either 5.2 g/day of n-3 PUFAs or
live oil, and observed a significant increase in the standard
eviation of R-R intervals in those allocated fish oil (8).
’Keefe et al. (9) allocated 18 men with an ejection fraction
40% after myocardial infarction either placebo or n-3
UFA capsules (585 mg DHA and 225 mg EPA daily) for
months, and noted, after active therapy, a significant fall
n HR and an increase in high-frequency (HF) HR spectral
ower but not low-frequency (LF) HR spectral power
which is primarily sympathetically mediated) (10).
If these markers of tonic vagal HR modulation are
mproved by n-3 PUFAs, it would be logical to assume that
sh oils also augment reflex vagal HR modulation. In this
ssue of the Journal, Radaelli et al. (11) have tested the
ypothesis that dietary n-3 PUFA supplementation en-
ances the arterial baroreflex control of both HR and blood
ressure (BP). Post-myocardial infarction non-diabetic pa-
ients with ejection fractions40% were randomly allocated
g/day of n-3 PUFAs (n  15) or placebo (n  10)
apsules. After 4 months of n-3 PUFAs, reflex depressor
nd bradycardic responses to stimulation of carotid barore-
eptors using graded-neck suction were augmented by 78%
nd 41%, respectively, and the alpha index of BRS (derived
rom cross-spectral analysis of BP and HR) increased by
6%; R-R interval variance increased by 50%, and HF-
RV power increased by 76%. A lack of BP effect suggested
hat these autonomic effects of PUFAs did not result from
reater afferent stimulation of arterial baroreceptors by
mproved hemodynamics. The authors concluded that, in
ddition to increasing HRV in stable mild-to-moderate
ongestive heart failure, n-3 PUFA supplementation aug-
ents vagal and sympathetic efferent responsiveness to
rterial baroreflex stimulation, and proposed that these
ctions might reduce the risk of SCD.
This carefully designed and executed study of post-infarct
atients, already treated with angiotensin-converting en-
yme inhibitors, beta-adrenoceptor antagonists, and statins,
emonstrates an additional effect of n-3 PUFA supplemen-
ation on several independent yet complementary markers of
utonomic circulatory control with known prognostic im-
lications. These observations stimulate 4 questions.
Why do these findings contrast with prior observations in
ealthy subjects? In young healthy men, supplementation
ith 4 weeks of fish oil (0.81 g EPA/day) had no effect on
eflex HR, forearm vasoconstrictor, or plasma norepineph-
ine responses to hypotensive (40 mm Hg) lower body
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Editorial Comment October 17, 2006:1607–9egative pressure, a maneuver that unloads both carotid and
ortic baroreceptors (12). More recently, Geelen et al. (13)
andomized 84 healthy women and men, age 50 to 70 years,
o 3 months of dietary supplementation with either fish (3.5
/day) or sunflower oil. Each of the LF alpha indexes for
RS, the SD of R-R variability, and HF and LF HRV
pectral power tended to decrease, rather than increase, in
hose receiving fish oil. Unclear is whether the discordance
etween the present observations and previous studies rep-
esent an action of n-3 PUFAs specific to the post-infarct
opulation (and if so, why?), an effect specific to barorecep-
or stimulation (11) as opposed to baroreceptor unloading
12), which elicits reflex sympathetic activation, or differ-
nces in baseline diet between these various populations.
Do these subjects reflect the heart failure population? Radaelli
t al. (11) describe their patients as having stable mild-to-
oderate congestive heart failure, yet only 52% were receiving
iuretics. Thus, many would be considered post-infarct pa-
ients with asymptomatic ventricular systolic dysfunction. This
onsideration becomes important when interpreting frequency
omain estimates of HRV, and in particular LF spectral power
10). Importantly, neither the BRS nor the HRV of subjects in
he present study were depressed to values shown to increase
he risk of SCD (1,14). Indeed, the mean alpha index reported
n the present study is similar to that described by this group in
ealthy men 50 years of age (15).
Only 1 of the 25 subjects in the present study was female.
omen, unlike men, may not respond to n-3 PUFA
upplementation (7,9,13). Thus, the autonomic effects of
-3 PUFA in both men and women with chronic conges-
ion, and in particular those at high risk because of severely
epressed HRV or BRS, should be determined before the
resent findings are applied broadly to the chronic heart
ailure population.
Is the assumption of clinical benefit appropriate? Whether
-3 PUFAs are anti-arrhythmic in humans remains contro-
ersial. Subsequent to their original paper, the DART
nvestigators reported a 29% increase in the risk of cardiac
eath and a 54% increase in the risk of SCD in men with
ngina advised to consume oily fish or fish oil capsules (16).
ecent trials involving patients at highest risk (i.e., those
ith implanted cardioverter-defibrillators [ICD]) for either
rimary or secondary prevention of SCD suggested little or
o benefit (17,18), and possibly harm (19). In those ran-
omized to 1.8 g/day of n-3 PUFAs versus placebo, Raitt et
l. (19) observed higher rates of ICD discharge elicited by
entricular tachycardia or fibrillation in patients with ven-
ricular tachycardia as their qualifying entry rhythm.
Do the present observations suggest a hypothesis to account for
hese findings? In addition to augmenting tonic and reflex
arkers of vagal HR modulation, randomization to n-3
UFAs resulted in a nearly 4-fold increase in LF HRV
pectral power and more than doubling of the LF/HF ratio
11). The neural mechanisms responsible for these changes
ere not elucidated. To do so would require quantification
f sympathetic outflow to the heart or to skeletal muscle10). The authors take the position that their observations
ere derived from patients with chronic congestive heart
ailure, in whom, paradoxically, LF spectral power is in-
ersely related to sympathetic discharge frequency (20), and
herefore should be interpreted as sympatho-inhibitory (11).
onversely, if these observations were derived from healthy
ubjects, or from well-compensated, non-edematous pa-
ients with mild or moderate left ventricular systolic dys-
unction (as appears to be the case for the present study),
uch changes may well reflect an increase in sympathetic
erve traffic (10,21,22). Because spectral analysis assesses
agal and cardiac sympathetic modulation of sino-atrial
ischarge within the HF and LF ranges, but not the
ntensity of nerve firing directed at the ventricles, the
ypothesis that n-3 PUFAs might exert a pro-arrhythmic
ction in heart failure, by augmenting reflexively sympa-
hetic outflow, cannot be dismissed without experiment. In
heir discussion, the authors acknowledge that they tested
nly the sympatho-inhibitory limb of the arterial baroreflex
nd therefore cannot exclude the possibility that PUFA
upplementation might enhance sympatho-excitatory re-
ponses to baroreflex unloading. Radaelli et al. (11) should
e congratulated for demonstrating that n-3 PUFAs can
mprove baroreflex health. We await with interest the results
f the GISSI Trial (23) of n-3 PUFA supplementation in
eart failure.
eprint requests and correspondence: Dr. John Floras, Divi-
ion of Cardiology, 1614-600 University Avenue, Toronto
5G 1X5, Ontario, Canada. E-mail: john.floras@utoronto.ca.
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